U.S. Biotech Stock News

Western Digital recently redeemed in full its 2.850% Senior Notes due 2029 and 3.100% Senior Notes due 2032 after repaying related secured debt, while also monetizing about US$3.17 billion of its SanDisk stake to reduce borrowings and simplify its balance sheet. At the same time, the company re-launched G-DRIVE as the single brand for its creative professional storage lineup, signaling a clearer focus on data‑center HDDs and creator workflows after its separation into a standalone hard drive...

Par Pacific Holdings (PARR) closed out FY 2025 with Q4 revenue of US$1.8 billion and basic EPS of US$1.58 on net income of US$77.7 million. Over the past four quarters, the company has reported revenue between US$1.7 billion and US$2.0 billion per quarter. Basic EPS moved from a quarterly loss of US$0.57 in Q1 2025 to a high of US$5.29 in Q3 2025, then finished at US$1.58 in Q4. For investors, that combination of solid Q4 profit and shifting EPS through the year highlights the question of how...

Natera (NTRA) shares are back in focus after the company reported Phase 2 SINERGY trial results in recurrent or metastatic head and neck cancer, highlighting strong response rates with less chemotherapy exposure and lower severe toxicity. See our latest analysis for Natera. At a share price of $211.83, Natera’s recent 1 day share price return of 1.10% contrasts with a 30 day share price return decline of 12.25%. Its 1 year total shareholder return of 31.93% and very large 3 year total...

Gen Digital and Vercel have partnered to bring AI driven security verification to Vercel's Skills.sh platform. The integration connects Gen Digital's Agent Trust Hub with developer workflows to provide risk ratings for AI agent skills. The move targets growing security concerns as AI agents are used for more autonomous and sensitive tasks. Gen Digital, listed as NasdaqGS:GEN, is tightening its focus on AI security with this partnership at a time when its share price stands at $22.29 and its...

Solstice Advanced Materials (SOLS) has caught investor attention after a strong share price move over the past month, prompting a closer look at how its current valuation lines up with its recent financial profile. See our latest analysis for Solstice Advanced Materials. The recent move has come on top of an already strong run, with a 30 day share price return of 29.9% and a 90 day share price return of 72.8%. This suggests momentum has been building rather than fading around the current...

Slide Insurance Holdings (SLDE) just wrapped up FY 2025 with fourth quarter revenue of US$347.0 million and basic EPS of US$1.38, while trailing twelve month revenue came in at US$1.2 billion with EPS of US$4.75. Over the past year, revenue has moved from US$846.8 million to US$1.2 billion and trailing EPS has stepped up from US$3.58 to US$4.75. This gives investors a clearer view of how the top line and per share profitability have tracked together. With trailing net profit margin at 38.4%...

Photronics (PLAB) is back in focus after issuing revenue guidance for its second quarter of fiscal 2026, projecting US$212 million to US$220 million, as investors also look ahead to the rescheduled earnings call. See our latest analysis for Photronics. The recent revenue guidance and upcoming earnings call arrive alongside strong momentum, with a 90 day share price return of 91.85% and a 1 year total shareholder return of 106.44%, suggesting sentiment has shifted meaningfully in Photronics'...

Atlanta Braves Holdings (BATRK) has just posted its FY 2025 third quarter numbers, with revenue of $311.5 million, basic EPS of $0.48 and net income of $30.0 million, giving investors a clear snapshot of how the season is flowing through to the bottom line. The company has seen quarterly revenue move from $282.9 million and EPS of $0.47 in Q2 FY 2024 to $290.7 million and $0.16 in Q3 FY 2024, then to $311.5 million and $0.48 in Q3 FY 2025. This sets up a narrative in which investors are...

In February 2026, Vicor Corporation reported its fourth-quarter 2025 and full-year 2025 results, with quarterly revenue of US$107.26 million and net income of US$46.53 million, while full-year revenue reached US$452.70 million and net income was US$118.56 million. Beyond the headline growth, Vicor paired this profit surge with active share repurchases and plans to expand chip fabrication capacity, underlining management’s confidence in sustained demand across AI, aerospace, defense, and...

Immunocore Holdings (IMCR) has reported third quarter FY 2025 revenue of US$103.7 million, with basic EPS of roughly US$0.00 and net income close to breakeven at a loss of US$0.2 million, giving investors a clear read on how the topline and bottom line are tracking this year. The company has seen quarterly revenue move from US$75.4 million in Q2 2024 to US$80.2 million in Q3 2024, US$84.1 million in Q4 2024, then US$93.9 million and US$98.0 million in Q1 and Q2 2025 before reaching US$103.7...

Why AptarGroup is on investors’ radar today AptarGroup (ATR) has attracted fresh attention after recent stock moves, with the share price around $142.68 and returns of about 13% over the past month and 15% in the past 3 months. At the same time, the company shows annual revenue growth of roughly 5% and net income growth close to 7%. This is supported by about $3.8b in revenue and $392.8m in net income across its pharma, beauty, and closures segments. See our latest analysis for...

Standard BioTools (LAB) has posted a mixed set of FY 2025 numbers, with Q4 revenue at US$23.8 million and basic EPS of US$0.04, even as trailing twelve month figures still show a loss with EPS at US$0.15 and net income from continuing operations at a loss of US$58.8 million. The company has seen quarterly revenue range from US$19.6 million to US$23.8 million across 2025, while basic EPS has moved between a loss of US$0.08 in Q3 and a small profit of US$0.04 in Q4. This sets up a story where...

Resideo Technologies (REZI) just closed out FY 2025 with Q4 revenue of US$1.9b and basic EPS of US$0.75, alongside net income of US$113m that capped off a trailing twelve month loss of US$562m and basic EPS of US$3.77 loss. The company has reported quarterly revenue between US$1.77b and US$1.94b over the past year, while EPS moved from a loss of US$5.48 in Q2 2025 to a profit of US$0.88 in Q3 and US$0.75 in Q4, so investors are watching how quickly margins can stabilise from here. See our...

Intuitive Surgical (ISRG) is back in focus after its Q4 2025 report showed 18.9% revenue growth, supported by higher procedure volumes and additional da Vinci system placements, along with positive commentary on the new da Vinci 5 platform. See our latest analysis for Intuitive Surgical. The Q4 2025 beat and enthusiasm around da Vinci 5 helped lift sentiment in the near term, with a 1 day share price return of 2.46% to US$506.17. However, the 90 day share price return of 11.85% and 1 year...

ICON Public Limited Company recently disclosed an internal accounting review indicating that revenues for fiscal years 2023 and 2024 were modestly overstated, leading to delayed Q4 and full-year 2025 results and attracting legal scrutiny over potential securities law violations. This episode is drawing attention because the company had previously reaffirmed its 2025 guidance and repurchased shares, raising questions about governance and disclosure practices. We’ll now examine how the...

Revolve Group (RVLV) has just posted its FY 2025 numbers, with fourth quarter revenue of US$324.4 million and basic EPS of US$0.26 on net income of US$18.6 million, capping a year where trailing twelve month revenue reached US$1.23 billion and EPS came in at US$0.87. The company has seen revenue move from US$293.7 million and EPS of US$0.17 in Q4 2024 to US$324.4 million and EPS of US$0.26 in Q4 2025, while trailing twelve month EPS stepped up from US$0.70 to US$0.87. This sets the backdrop...

Gilead Sciences (NasdaqGS:GILD) has agreed to acquire Arcellx in a $7.8b deal, expanding its presence in cell therapies for blood cancers. The acquisition adds a near-approval CAR T cell therapy candidate to Gilead’s oncology portfolio. Separately, Gilead reported new Phase 3 data for an investigational once daily, single tablet HIV regimen, showing noninferior efficacy and high tolerability versus existing treatments. For investors watching Gilead Sciences at a share price of $147.12,...

Taboola.com (TBLA) closed out FY 2025 with Q4 revenue of US$522.3 million and basic EPS of US$0.17, alongside Q4 2024 figures of US$491.0 million in revenue and basic EPS of US$0.10. Over the latest reported periods, revenue has moved from US$433.0 million in Q3 2024 to US$496.8 million in Q3 2025, while basic EPS shifted from a loss of US$0.02 to a profit of US$0.02. This highlights a story in which improving profitability and tighter margins are front and center for investors assessing this...

FrontView REIT (FVR) has just wrapped up FY 2025 with Q4 total revenue of US$16.5 million and basic EPS of a US$0.19 loss, capping a trailing twelve month stretch that totaled US$66.0 million in revenue and basic EPS of US$0.18. Over the last few reported quarters, revenue has moved from US$15.5 million in Q4 2024 to US$16.5 million in Q4 2025, while quarterly EPS has swung between earnings of US$0.19 and losses of around US$0.16 as margins absorbed a large one off loss of US$17.6 million...

BKV (BKV) closed out FY 2025 with Q4 revenue of US$330.1 million and basic EPS of US$0.76, while trailing twelve month EPS sat at US$2.00 on revenue of US$1.0 billion and net income of US$173.1 million. Over the past year, revenue has moved from US$615.1 million and a loss of US$2.00 per share on the trailing twelve month basis in Q4 2024 to US$1.0 billion and EPS of US$2.00. This frames a clear shift in reported profitability for the period. For investors, that combination of higher sales,...

Valens Semiconductor FY 2025 Earnings Snapshot Valens Semiconductor (VLN) just posted third quarter FY 2025 revenue of US$17.3 million with a basic EPS loss of US$0.07, alongside trailing twelve month revenue of US$67.9 million and a TTM basic EPS loss of US$0.29. The company has seen quarterly revenue move from US$13.6 million in Q2 2024 to US$17.3 million in Q3 2025, while quarterly EPS losses have ranged between US$0.07 and US$0.10 over the same stretch. Investors are likely to focus on...

Dine Brands Global (DIN) has laid out its FY 2025 scorecard with Q3 revenue of US$216.2 million and basic EPS of US$0.48, alongside net income of US$7.0 million, setting the tone for how the full year is shaping up. The company has seen quarterly revenue move from US$204.8 million in Q4 2024 to US$214.8 million in Q1 2025, US$230.8 million in Q2 2025, then US$216.2 million in Q3 2025. Over the same period, EPS shifted from US$0.34 to US$0.53, US$0.89 and then US$0.48. With trailing net profit...

Recursion Pharmaceuticals (RXRX) just posted another heavily loss making quarter, with Q3 FY 2025 revenue of US$5.2 million against a net loss of US$162.3 million and basic EPS of a US$0.36 loss. The company has seen quarterly revenue move between US$26.1 million in Q3 FY 2024 and US$4.5 million in Q4 FY 2024, while quarterly EPS has ranged from a US$0.34 loss to a US$0.53 loss over that period. This underscores a business that is still in investment mode rather than profit harvesting. For...

Axcelis Technologies reported past fourth-quarter 2025 revenue of US$238.33 million and net income of US$34.3 million, alongside full-year 2025 revenue of US$839.05 million and net income of US$120.24 million, and later issued first-quarter 2026 guidance for about US$195 million in revenue and GAAP diluted EPS of US$0.38. The combination of weaker year-on-year results and more cautious near-term guidance gives investors fresh information on how Axcelis is managing softer semiconductor...